150 related articles for article (PubMed ID: 28094183)
1. Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors.
Feneyrolles C; Guiet L; Singer M; Van Hijfte N; Daydé-Cazals B; Fauvel B; Chevé G; Yasri A
Bioorg Med Chem Lett; 2017 Feb; 27(4):862-866. PubMed ID: 28094183
[TBL] [Abstract][Full Text] [Related]
2. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
[TBL] [Abstract][Full Text] [Related]
4. Curcumin-Synthetic Analogs Library Screening by Docking and Quantitative Structure-Activity Relationship Studies for AXL Tyrosine Kinase Inhibition in Cancers.
Ghrifi F; Allam L; Wiame L; Ibrahimi A
J Comput Biol; 2019 Oct; 26(10):1156-1167. PubMed ID: 31009237
[No Abstract] [Full Text] [Related]
5. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
[TBL] [Abstract][Full Text] [Related]
6. Research Progress of Axl Inhibitors.
Sun ZG; Liu JH; Zhang JM; Qian Y
Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.
Szabadkai I; Torka R; Garamvölgyi R; Baska F; Gyulavári P; Boros S; Illyés E; Choidas A; Ullrich A; Őrfi L
J Med Chem; 2018 Jul; 61(14):6277-6292. PubMed ID: 29928803
[TBL] [Abstract][Full Text] [Related]
8. The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.
Gajiwala KS; Grodsky N; Bolaños B; Feng J; Ferre R; Timofeevski S; Xu M; Murray BW; Johnson TW; Stewart A
J Biol Chem; 2017 Sep; 292(38):15705-15716. PubMed ID: 28724631
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors.
Choi MJ; Roh EJ; Hur W; Lee SH; Sim T; Oh CH; Lee SH; Kim JS; Yoo KH
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3761-3765. PubMed ID: 30340900
[TBL] [Abstract][Full Text] [Related]
10. Development linear and non-linear QSAR models for predicting AXL kinase inhibitory activity of N-[4-(quinolin-4-yloxy)phenyl]benzenesulfonamides.
Ahmadi R; Sepehri B; Ghavami R
J Recept Signal Transduct Res; 2019 Jun; 39(3):264-275. PubMed ID: 31538847
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
Xu C; Han Y; Xu S; Wang R; Yue M; Tian Y; Li X; Zhao Y; Gong P
Eur J Med Chem; 2020 Jan; 186():111867. PubMed ID: 31757525
[TBL] [Abstract][Full Text] [Related]
12. AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.
Myers SH; Brunton VG; Unciti-Broceta A
J Med Chem; 2016 Apr; 59(8):3593-608. PubMed ID: 26555154
[TBL] [Abstract][Full Text] [Related]
13. Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
Keung W; Boloor A; Brown J; Kiryanov A; Gangloff A; Lawson JD; Skene R; Hoffman I; Atienza J; Kahana J; De Jong R; Farrell P; Balakrishna D; Halkowycz P
Bioorg Med Chem Lett; 2017 Feb; 27(4):1099-1104. PubMed ID: 28082036
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.
Zhang H; Peng X; Dai Y; Shao J; Ji Y; Sun Y; Liu B; Cheng X; Ai J; Duan W
J Med Chem; 2021 Apr; 64(7):3956-3975. PubMed ID: 33733758
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
Xu D; Sun D; Wang W; Peng X; Zhan Z; Ji Y; Shen Y; Geng M; Ai J; Duan W
Eur J Med Chem; 2021 Aug; 220():113497. PubMed ID: 33957388
[TBL] [Abstract][Full Text] [Related]
16. In Silico Approach to Identify Potential Inhibitors for Axl-Gas6 Signaling.
Peter SC; Mannu J; Mathur PP
Methods Mol Biol; 2017; 1549():221-229. PubMed ID: 27975295
[TBL] [Abstract][Full Text] [Related]
17. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
[TBL] [Abstract][Full Text] [Related]
18. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
Ghosh AK; Secreto C; Boysen J; Sassoon T; Shanafelt TD; Mukhopadhyay D; Kay NE
Blood; 2011 Feb; 117(6):1928-37. PubMed ID: 21135257
[TBL] [Abstract][Full Text] [Related]
19. Recent discovery and development of AXL inhibitors as antitumor agents.
Liu Z; Chen L; Zhang J; Yang J; Xiao X; Shan L; Mao W
Eur J Med Chem; 2024 Jun; 272():116475. PubMed ID: 38714043
[TBL] [Abstract][Full Text] [Related]
20. Cell- and Tissue-Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase Inhibitor.
Zheng B; Guo H; Ma N; Ni Y; Xu J; Li L; Hao P; Ding K; Li Z
Chem Asian J; 2018 Sep; 13(18):2601-2605. PubMed ID: 29939481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
